Related Experiment Video
Updated: Feb 16, 2026
Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip
Dong Woo Lee1, Sang-Yun Lee2, Il Doh3
1Department of Biomedical Engineering, Konyang University, Daejeon 35365, Republic of Korea.
Abstract:
Glioblastoma multiforme (GBM) is recognized as the most common and lethal form of central nervous system cancer. To cure GBM patients, many target-specific chemotherapeutic agents have been developing. However, 2D monolayer cell-based toxicity and efficacy tests did not efficiently screen agents due to the pool reflection of in vivo microenvironments (cell-to-cell and cell-to-extracellular matrix interaction). In this study, we used a 3D cell-based, high-throughput screening method reflecting the microenvironments using a micropillar and microwell chip platform to draw a high-dose heat map of the cytotoxicity and efficacy of 70 compounds, with two DMSO controls. Moreover, the high-dose heat map model compared the responses of four 3D-cultured patient-derived GBM cells and astrocytes to high dosages of compounds with respect to efficacy and cytotoxicity, respectively, to discern the most efficacious drug for GBM. Among the 70 compounds tested, cediranib (a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases) exhibited the lowest cytotoxicity to astrocytes and high efficacy to GBM cells in a high-dose heat map model.
Insights
A novel 3D high-throughput screening method identified cediranib as a promising glioblastoma multiforme (GBM) treatment. This approach better reflects the in vivo microenvironment for drug discovery compared to traditional 2D methods.
Area of Science:
- Neuro-oncology
- Drug Discovery
- Biotechnology
Background:
- Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor.
- Current 2D cell-based assays inadequately mimic the in vivo tumor microenvironment, limiting effective drug screening.
- Developing novel therapeutic strategies for GBM remains a critical unmet medical need.
Purpose of the Study:
- To develop and validate a 3D high-throughput screening platform for evaluating chemotherapeutic agents against GBM.
- To compare the efficacy and cytotoxicity of 70 compounds using this advanced 3D model.
- To identify potent and safe drug candidates for GBM treatment.
Main Methods:
- Utilized a micropillar and microwell chip platform for 3D cell culture.
- Implemented a high-throughput screening approach to generate high-dose heat maps of compound efficacy and cytotoxicity.
- Tested 70 compounds, including two DMSO controls, against 3D-cultured patient-derived GBM cells and astrocytes.
Main Results:
- The 3D model effectively simulated the in vivo microenvironment for drug screening.
- Cediranib demonstrated significant efficacy against GBM cells while exhibiting low cytotoxicity towards astrocytes.
- A high-dose heat map effectively visualized differential compound responses.
Conclusions:
- The developed 3D cell-based screening platform offers a more predictive model for GBM drug discovery.
- Cediranib shows potential as a targeted therapeutic agent for glioblastoma, warranting further investigation.
- This platform facilitates the identification of drugs with favorable efficacy and safety profiles for GBM.
